Pegcetacoplan for 52 Weeks Results in Sustained Proteinuria Reduction to Remission (≤0.5 g/g) and Normalization (≤0.2 g/g): Phase 3 VALIANT Trial

Carla Nester; Fádi Fakhouri; Daniel P. Gale; Andrew S. Bomback; Christoph Licht; Giuseppe Remuzzi; Nicole C. A. J. van de Kar; K. Gordon; Anwesha Mukherjee; Johan Szamosi; Lucía Quintana; Matthew C. Pickering

doi:10.1681/asn.2025da4gcc32

Related publications

Article2025

Pegcetacoplan for 52 Weeks Maintains Proteinuria Reduction Regardless of Immunosuppressant Use or Nephrotic-Range Proteinuria at Baseline: VALIANT Subgroup Analysis

Carla Nester, Andrew S. Bomback, María Gema Ariceta Iraola, Yahsou Delmas, Bradley P. Dixon, Daniel P. Gale, Larry A. Greenbaum, Seung Hyeok Han, Nicole M. Isbel, Christoph Licht, Antonio Mastrangelo, Masashi Mizuno, Maria Izabel Neves de Holanda, Matthew C. Pickering, Giuseppe Remuzzi, Nicole C. A. J. van de Kar, Marina Vivarelli, Patrick D. Walker, Dean Wallace, Daniel Zecher, Moglie Le Quintrec, Yael Borovitz, Nabil Melhem, Fádi Fakhouri

Article2025

#3265 Pegcetacoplan treatment effect in patients with nephrotic range proteinuria: results from the VALIANT Phase 3 study in patients with C3G or primary (idiopathic) IC-MPGN

Marina Vivarelli, Andrew S. Bomback, Gema Ariceta, Antonio Mastrangelo, Carla Nester, Giuseppe Remuzzi, Nicole C. A. J. van de Kar, Zhongshen Wang, Johan Szamosi, Dima Decker, Lenny Gallardo, Fádi Fakhouri

Article2025

#3391 Pegcetacoplan treatment appears to halt disease progression in C3G and primary (idiopathic) IC-MPGN patients: results from the phase 3 VALIANT study

Daniel P. Gale, Andrew S. Bomback, Christoph Licht, Carla Nester, Matthew C. Pickering, Giuseppe Remuzzi, Nicole C. A. J. van de Kar, Zhongshen Wang, Johan Szamosi, Dima Decker, Luis Fernando Barba-Gallardo, Fádi Fakhouri

Article2025

VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN

Carla Nester, Andrew S. Bomback, Gema Ariceta, Yahsou Delmas, Bradley P. Dixon, Daniel P. Gale, Larry A. Greenbaum, Seung Hyeok Han, Nicole M. Isbel, Christoph Licht, Antonio Mastrangelo, Masashi Mizuno, Maria Izabel Neves de Holanda, Matthew C. Pickering, Giuseppe Remuzzi, Nicole C. A. J. van de Kar, Marina Vivarelli, Patrick D. Walker, Dean Wallace, Daniel Zecher,

Article2023

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52 Weeks in the Phase 3 POETYK PSO-1 Trial

Mark Lebwohl, Melinda Gooderham, Richard B. Warren, Diamant Thaçi, Peter Foley, Alice B. Gottlieb, Lauren Hippeli, Renata M. Kisa, Subhashis Banerjee, Christopher Em Griffiths

Pegcetacoplan for 52 Weeks Results in Sustained Proteinuria Reduction to Remission (≤0.5 g/g) and Normalization (≤0.2 g/g): Phase 3 VALIANT Trial

Discussion(0)

Related publications

Pegcetacoplan for 52 Weeks Maintains Proteinuria Reduction Regardless of Immunosuppressant Use or Nephrotic-Range Proteinuria at Baseline: VALIANT Subgroup Analysis

#3265 Pegcetacoplan treatment effect in patients with nephrotic range proteinuria: results from the VALIANT Phase 3 study in patients with C3G or primary (idiopathic) IC-MPGN

#3391 Pegcetacoplan treatment appears to halt disease progression in C3G and primary (idiopathic) IC-MPGN patients: results from the phase 3 VALIANT study

VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52 Weeks in the Phase 3 POETYK PSO-1 Trial